Regeneron Pharmaceuticals (LTS:0R2M) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R2M Regeneron Pharmaceuticals Inc LTS:0R2M
91 GF Score
Price $798.17
GF Value $902.81
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

LTS:0R2M
91GF Score
Regeneron Pharmaceuticals Inc LTS:0R2M
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Regeneron Pharmaceuticals (LTS:0R2M) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of $798.17 is trading 11.6% below its estimated GF Value™ of $902.81. GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for LTS:0R2M:

  • Interest Expense (Positive):
  • GF Value™: $902.81 vs. price of $798.17 (11.6% below fair value)
  • GF Score™: 91/100 with 6 warning signs

No single metric tells the full story. See the LTS:0R2M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals is a biotechnology company known for inventing its medicines internally through proprietary technologies including VelocImmune mice that produce fully human antibodies. Its two flagship franchises are Eylea and higher-dose Eylea HD for retinal diseases, facing biosimilar pressure, and Dupixent, the immunology blockbuster partnered with Sanofi that continues rapid growth across atopic dermatitis, asthma, COPD, and other indications. The oncology portfolio includes Libtayo and expanding bispecific antibodies Lynozyfic, odronextamab, and others, while the pipeline spans obesity combinations, genetic medicines with Alnylam and Intellia partnerships, and allergy. The Regeneron Genetics Center runs one of the world's largest human sequencing efforts to inform target discovery. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron is headquartered in Tarrytown, New York.
91GF Score

Get the complete analysis for LTS:0R2M

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$798.17
Price
$902.81
GF Value